Microbot Medical Inc. (MBOT)
| Previous close | 0.8772 |
| Open | 0.8700 |
| Bid | 0.6160 x 200 |
| Ask | 1.1400 x 200 |
| Day's range | 0.8700 - 0.8800 |
| 52-week range | 0.8600 - 4.3700 |
| Volume | |
| Avg. volume | 102,172 |
| Market cap | 12.671M |
| Beta (5Y monthly) | 1.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Microbot Medical Shares Status Following Recent Geopolitical Events
All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes that Both Regulatory and Commercial Milestones to be Achieved in Accordance with the Company’s Current Timeline BRAINTREE, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY® Endovascular Robotic Surgical System, today shared that despite the unprecedented events in Israel yesterday, which are
- GlobeNewswire
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this applicationBRAINTREE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY® Endovascular Robotic Surgical System, announced that it has filed an Investigational Device Exemption (IDE) application with the US Food and Drug Administration (FDA). The IDE application follows the completion of multiple preclinical activities per
- GlobeNewswire
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
All of the cash payable to the plaintiffs in the settlement will be covered by Microbot’s insurance carrier and will not impact company's cash positionBRAINTREE, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced it has signed a Settlement Agreement and Release with Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd. that
